Outcome results in children with IgA nephropathy: a single center experience by Bulut, Ipek Kaplan et al.
© 2012 Kaplan Bulut et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nephrology and Renovascular Disease 2012:5 23–28
International Journal of Nephrology and Renovascular Disease
Outcome results in children with IgA nephropathy: 
a single center experience
Ipek Kaplan Bulut1
Sevgi Mir1
Betul Sozeri1
Mustafa Orhan Bulut2
Sait Sen3
Nida Dincel1
1Ege University Faculty of Medicine 
Department of Pediatric Nephrology, 
2Ege University Faculty of Medicine 
Department of Pediatrics, Izmir, 
3Ege University Faculty of Medicine 
Department of Pathology,  
Izmir, Turkey
Correspondence: Ipek Kaplan Bulut 
Ege University, Faculty of Medicine, 
Department of Pediatric Nephrology, 
35100, Izmir, Turkey 
Tel +90 533 6596809 
Fax +90 232 3901357 
Email ikaplanbulut@gmail.com
Background: Immunoglobulin A nephropathy (IgAN) is the most common primary 
  glomerulonephritis. Patients manifest variable clinical symptoms (eg, microhematuria) with 
preserved or progressive deterioration of renal function resulting in end-stage renal disease. The 
aim of this study was to evaluate patients from a single center to describe the clinical features, 
treatments, and follow-up results of those with the disease.
Methods: This is a retrospective data study of all children with IgAN. Patients who had a 
histopathologically proven diagnosis of IgAN and were followed up for at least 5 years were 
included in the study. Renal biopsy, graded as Hass classification, was performed on all patients. 
A total of 39 patients were included in the study.
Results: The mean follow-up time (± standard deviation) was 10.4 ± 3.51 (range 5–16) years. 
Twenty-nine patients (74.4%) were male and ten (25.6%) were female. Nineteen (48.7%) patients 
presented with recurrent macroscopic hematuria, ten (25.6%) with microscopic hematuria ± 
proteinuria, six (15.4%) with nephritic syndrome, and four (10.3%) with nephrotic syndrome. 
All patients underwent a renal biopsy, which was graded according to the Hass classification. 
At the end of follow-up time, 18 (46.1%) patients were normal, 15 (38.5%) had minor urinary 
abnormalities, three (7.7%) had active renal disease, and three (7.7%) developed renal failure.
Conclusion: The results of the present study are better than those from most other series. The 
majority of children with IgAN in this study were admitted with recurrent macroscopic hematuria 
and found to have a good prognosis. We suggest that children with IgAN have a good prognosis 
in the first 5-year follow-up period.
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Introduction
Immunoglobulin A (IgA) nephropathy (IgAN) is the most common form of glomerulo-
nephritis in children and adolescents worldwide.1,2 The disease was described as a new 
clinical entity in 1968.2 Kidney biopsy is essential for diagnoses that show a markedly 
expanded mesangium filled with IgA. The clinical presentation of IgAN varies across the 
spectrum of initial renal manifestations, ranging from microscopic hematuria to end-stage 
renal disease (ESRD). The prognosis was initially considered to be benign in children but 
long-term studies have shown that IgAN in children can follow the same progression as in 
adults.3,4 Furthermore, previous studies on this subject have shown that ESRD will occur 
in 6%–43% of patients with IgA nephropathy over a period of 10 years. Several factors 
affect the prognosis in patients with IgA nephropathy, such as elevated serum creatinine, 
heavy proteinuria, hypertension, and sex (with males more likely to have the disease).5
The aim of this study was to evaluate patients from a single center to describe the 
clinical features, treatments, and follow-up results of those with the disease.
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Patients and methods
This is a retrospective data study of all children with IgAN 
hospitalized at the Ege University, Faculty of Medicine, 
Department of Pediatric Nephrology, from January 1991 
to December 2005. Patients who had a histopathologically 
proven diagnosis of IgAN and were followed up for at least 
5 years were included in the study. All medical records were 
reviewed with emphasis on presenting symptoms, physical 
exam findings, laboratory data, therapies, and outcome. 
The local ethical committe approved all procedures in this 
study.
For each patient, the following information was com-
pleted from medical charts: patient age at time of biopsy, sex, 
serum creatinine (mg/dL), serum IgA levels; urinary protein 
excretion (g/24 hours or protein/creatinine ratio); presence or 
absence of gross and/or microscopic hematuria; and presence 
or absence of hypertension (blood pressure .95th percen-
tile for age, gender, and height on repeated measurements). 
Hematuria was defined as a small amount (+) of hemoglobin 
on dipstick testing or greater than five red blood cells per 
high-power microscopic field in a centrifuged specimen.
Proteinuria was defined as a small amount of   protein (+) on 
dipstick testing or proteinuria greater than 0.5 g/1.73 m2/day 
obtained from urine collected over 24 hours. The Schwartz 
formula was used to estimate creatinine clearance from 
the serum creatinine and height. Low creatinine clear-
ance was defined as an estimated glomerular filtration 
rate (GFR) of ,60 mL/min per 1.73 m2 body surface 
area. These patients were classified according to the ini-
tial clinical presentation.6 This classification was used as 
  follows: microscopic hematuria ± proteinuria; macroscopic 
hematuria; nephritic syndrome (hematuria, decrease in 
GFR, oliguria, hypertension, edema); nephrotic syndrome 
(  proteinuria .40 mg/m2/h, hypoalbuminemia, hyperlipi-
demia, and edema). Histopathologic examination was done 
by the same pathologist. Renal biopsies, all of which con-
tained at least ten glomeruli, were processed for light and 
immunofluorescence microscopy. In light microscopy, biop-
sies were graded from I to V in increasing severity according 
to the Hass classification7 grades as follows: Grade I, normal 
histology or mild increase in   mesangial matrix, without 
segmental lesions; Grade II, focal and segmental glomerular 
sclerosis, without   glomerular hypercellularity or crescents; 
Grade III, focal (involving #50% of glomeruli present, 
exclusive of globally sclerotic glomeruli)   mesangial and/or 
endocapillary proliferative glomerulonephritis; Grade IV, 
diffuse (involving .50% of glomeruli present, exclusive of 
globally sclerotic glomeruli) mesangial and/or endocapillary 
proliferative glomerulonephritis; Grade V , advanced chronic 
glomerulonephritis, characterized by $40% globally sclerotic   
glomeruli and/or $40% interstitial fibrosis/tubular atrophy 
in the cortical tissue present, regardless of other histologic 
features. Mesengial IgA deposits are the defining hallmark 
of the disease in immunofluorescence microscopy.
Patients were placed into one of three treatment groups, 
as follows: (1) patients with recurrent macroscopic hematuria 
without proteinuria, and with normal kidney function, were 
treated with nonspecific therapy (omega-3:fish oil); (2) patients 
with proteinuria (range 0.5–3 g/1.73 m2/day) with or without 
microscopic hematuria had angiotensin converting enzyme 
inhibitors (ACEIs) and fish oil; and (3) patients with nephrotic 
syndrome had corticosteroid therapy (prednisolone or pulse 
methylprednisolone). Cytotoxic therapy was given when no 
response was observed following corticosteroid therapy.
Clinical outcome was graded as follows: A,   normal 
(no hypertension, no urinary abnormality and no   protein 
excretion and normal plasma creatinine concentration); 
B, minor urinary abnormalities (proteinuria ,1 g/1.73 m2/day 
with or without microscopic-recurrent macroscopic   hematuria); 
C, active renal disease (proteinuria .1 g/1.73 m2/day and/or 
elevated plasma creatinine level); or D, renal insufficiency   
(GFR ,60 mL/min/1.73 m2).
Statistical analysis
Categorical data and proportions were compared using the 
chi-square test or Fisher’s exact test, as indicated. Means 
were compared by Student’s t-test, and medians were com-
pared using the Mann–Whitney U test. The Kruskal–Wallis 
test was applied to the ordinal variables. A value of P , 0.05 
was considered statistically significant. SPSS (v 11.0; SPSS 
Inc, Chicago, IL) software was used for statistical analysis.
Results
A total of 39 patients were included in the study. The mean 
follow-up time (± standard deviation [SD]) was 10.4 ± 3.51 
(range 5–16) years. Twenty-nine (74.4%) were male and ten 
(25.6%) female. Males were affected more often than females 
(males:females = 3:1). The mean age (±SD) of the patients 
at onset of the disease was 9.5 ± 3.75 years (range 4–17). 
Elevated serum creatinine and hypertension were detected in 
7.7% and 10.3% of patients, respectively. Nineteen (48.7%) 
patients presented with recurrent macroscopic hematuria, 
ten (25.6%) with microscopic hematuria ± proteinuria, six 
(15.4%) with nephritic syndrome, and four (10.3%) with 
nephrotic syndrome. The demographic and clinical findings 
of patients are shown in Table 1.
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All patients underwent renal biopsy. Immunofluorescence 
study showed IgA deposition in the glomerular mesangium 
in all specimens. Light microscopic findings of biopsies 
were: 22 (56.4%) patients, Grade I; four (10.2%), Grade II; 
eleven (28.3%), Grade III; and two (5.1%), Grade IV . There 
were no patients in advanced chronic glomerulonephritis 
(Grade V).
All patients in the study received fish oil after   diagnosis. 
Twenty-nine (74.4%) patients were treated with ACEIs, and 
ten (25.6%) with corticosteroids. Three (7.7%) patients had 
corticosteroid plus cytotoxic agents including cyclosporine-A, 
cyclophosphamide, and azathiopurine. Four patients with 
nephrotic syndrome, three patients with nephritic syndrome, 
two patients with hematuria ± proteinuria, and one patient 
with recurrent macroscopic hematuria were given steroid 
therapy (Table 2).
At the end of follow-up time, 18 (46.1%) patients were 
normal, 15 (38.5%) had minor urinary abnormalities, three 
(7.7%) had active renal disease, and three (7.7%) devel-
oped renal failure. The relationship between initial clinical 
  findings, biopsy findings, and outcomes of the patients is 
shown in Table 3.
All patients were evaluated according to risk factors at 
admission. Three patients with elevated serum creatinine 
levels presented with recurrent macroscopic hematuria. 
These patients had Grade III renal biopsy specimens. Two of 
these patients entered remission while one had minor urinary 
abnormalities at last follow-up time.
Four (10.3%) of 39 patients had hypertension on 
  admission. Two patients presented with recurrent macro-
scopic hematuria, and two with microscopic hematuria ± 
proteinuria. Three patients had Grade I, one had Grade IV . 
One of these four patients achieved remission, one had minor 
urinary abnormalities, one had active renal disease, and one 
developed renal failure at last follow-up (Table 4).
At onset, 20 patients had proteinuria (.1 g/day). Two 
of these had active renal disease while two developed renal 
failure at last follow-up time.
Discussion
This study evaluated initial clinical features, treatment 
modalities, and outcome in children with IgAN. Thirty-nine 
patients with IgAN were retrospectively reviewed over a 
15-year period.
IgAN occurs at all ages but is most common during the 
second and third decades of life and uncommon in those 
under the age of 3 years.6,8 The peak incidence of IgA 
nephropathy in children occurs between 9 and 10 years of 
age.2 In the present study, the mean age at disease onset was 
9.5 ± 3.7 years. Primary IgAN is more frequent in males than 
females.2 The male to female ratio in this study was 3:1.
The clinical presentation of IgAN is not pathognomonic. 
Asymptomatic microscopic hematuria can be found in 60% 
of subjects. Recurrent macroscopic hematuria continues 
to occur in 20%–80% of these patients.1,9,10 Some cases 
may present with acute nephritic syndrome and acute renal 
  failure.6 In the present study, patients presented with recurrent 
macroscopic hematuria, microscopic hematuria ± proteinuria, 
nephritic syndrome, and nephrotic syndrome (48.7%, 25.6%, 
15.4%, 10.3%, respectively). It is suggested that recurrent 
Table 1 The demographic and clinical features in 39 children 
with immunoglobulin A nephropathy
Features n
Age at initial onset (year) 
Mean ± SD (range)
9.5 ± 3.75 (4–17)
Sex 
Male/female
 
29/10
high levels of serum IgA (n [%]) 16 (41)
Recurrent macroscopic hematuria (n [%]) 19 (48.7)
hematuria ± proteinuria (n [%]) 10 (25.6)
Nephritic syndrome (n [%]) 6 (15.4)
Nephrotic syndrome (n [%]) 4 (10.3)
Table 2 Outcome of patients given steroid treatment
Initial presentation Treatment Outcome*
Nephrotic syndrome (n = 4) 2 patients ACEIs + fish oil + steroid + CA** D
1 patient ACEIs + fish oil + steroid C
1 patient ACEIs + fish oil + steroid A
Nephritic syndrome (n = 3) 2 patients ACEIs + fish oil + steroid B
1 patient ACEIs + fish oil + steroid A
hematuria ± proteinuria (n = 2) 1 patient ACEIs + fish oil + steroid + CA** D
1 patient ACEIs + fish oil + steroid C
Recurrent macroscopic hematuria (n = 1) 1 patient ACEIs + fish oil + steroid C
Notes: *Outcome: A, normal; B, minor urinary abnormalities; C, active renal disease; D, end-stage renal disease; **cytotoxic agents (CA): cyclosporine-A, cyclophosphamide, 
azathiopurine.
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macroscopic hematuria is the most important presentation 
and seen more often than acute renal failure, a result similar 
to studies from Europe and United States.6
Hypertension is infrequently present at disease onset 
and, when present, is usually mild to moderate in severity 
and relatively easy to control.1,2 Likewise, decreased renal 
function rarely presents at disease onset.9 Ronkainen et al 
reported that hypertension at onset was present in 13% of 
the patients.1 Hypertension at onset was not common in 
the present series: only four (10.3%) of the 39 patients had 
hypertension. One of these developed ESRD and another one 
had persistent, active renal disease at the end of follow-up. 
Three (7.7%) of the 39 patients had elevated serum creatinine 
at onset. Patients who present with hypertension at disease 
onset should receive careful follow-up.
In the literature, higher serum IgA levels were detected in 
35%-70% of patients with IgAN.6,10 This marker may suggest 
the possible presence of disease. High levels of IgA are found 
during the phases of clinical activity.11 In the present study, 
41% of patients had elevated serum IgA at onset of disease.
The range of pathologic features of IgAN has been well 
described. Hass found that the most common histological 
lesions are focal proliferative glomerulonephritis, accounting 
for between 40% and 50% in both adults and children.7 
In the Hass study, biopsies showing normal histology 
were more common in children than in adults (27%, 
14%, respectively).7 In immunofluorescence microscopy, 
mesengial diffuse IgA deposits are the defining hallmark 
of the disease.12   Immunoglobulin G, immunoglobulin M, 
and Complement 3 deposition may accompany IgA.13 In the 
present study, renal biopsy was performed in all patients. 
The immunofluorescence study showed IgA deposition 
in the glomerular mesangium in all specimens. Minimal 
histologic lesion (Grade I) was most commonly seen in 
the patients (56.4%). Focal proliferative glomerulonephri-
tis (Grade III) and focal segmental glomerular sclerosis 
without proliferation (Grade II) accounted for 28.4% and 
10.2%, respectively. Eleven patients in the study had diffuse 
proliferative findings (Grade III) and seven presented with 
recurrent macroscopic hematuria at onset of disease. These 
results suggest that first clinical findings are not related to 
renal biopsy findings. Therefore, patients with IgAN should 
undergo renal biopsy irrespective of initial symptoms.
The optimal approach to the treatment of IgA nephropathy 
is still uncertain. There are four separate approaches to IgA 
nephropathy:14–16 (1) patients with recurrent macroscopic 
hematuria with normal renal function, no proteinuria, and 
no microscopic hematuria between episodes are treated with 
nonspecific therapy (fish oil); (2) patients with persistent 
proteinuria (0.5–1 g/1.73 m2/day) ± microscopic hematuria 
might be treated with ACEIs; (3) patients with proteinuria 
(1–3 g/1.73 m2/day) persisting, despite ACEI/angiotensin 
receptor–blocker therapy, are treated with corticosteroid; 
and (4) patients with proteinuria (.3.5 g/1.73 m2/day) and/or 
rising serum creatinine, and/or renal biopsy with more severe 
histologic findings may benefit from   immunosuppressive 
Table 3 Clinical findings, biopsy findings, and outcome results 
of all patients
Initial clinical findings Biopsy Outcome*
A B C D
Recurrent macroscopic  
hematuria (n = 19)
grade I 
grade II 
grade III
6 
1 
2
4 
1 
5
– 
– 
–
– 
– 
–
hematuria ± proteinuria  
(n = 10)
grade I 
grade III 
grade IV
3 
2 
–
2 
– 
1
1 
– 
–
1 
– 
–
Nephritic syndrome (n = 6) grade I 
grade II
3 
–
1 
1
– 
1
– 
–
Nephrotic syndrome (n = 4) grade I 
grade III 
grade IV
1 
– 
–
– 
– 
–
– 
1 
–
– 
1 
1
Note: *Outcome: A, normal; B, minor urinary abnormalities; C, active renal disease; 
D, end-stage renal disease.
Table 4 Patients with elevated serum creatinine and hypertension at onset
Initial presentation Biopsy Therapy Outcome*
Elevated serum  
creatinine
Recurrent macroscopic hematuria Patient 1 grade III ACEIs + fish oil B
Patient 2 grade III ACEIs + fish oil A
Patient 3 grade III ACEIs + fish oil A
hypertension Recurrent macroscopic hematuria Patient 1 grade I ACEIs + fish oil A
Patient 2 grade I ACEIs + fish oil B
Microscopic hematuria ± proteinuria Patient 1 grade IV ACEIs + fish oil + steroid C
Patient 2 grade I ACEIs + fish oil + steroid + CA** D
Notes: *Outcome: A, normal; B, minor urinary abnormalities; C, active renal disease; D, end-stage renal disease; **cytotoxic agents (CA): cyclosporine-A, cyclophosphamide, 
azathiopurine.
Abbreviation: ACEIs, angiotensin converting enzyme inhibitors.
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therapy in addition to corticosteroids. Donadio et al provided 
evidence that those patients who received omega 3 fatty acids 
(fish oil) for 2 years had a good prognosis.17 Hogg et al found 
parallel results.18 The lack of any significant side-effects and 
the potential for benefit make omega 3 fatty acid prepara-
tions an attractive initial option for patients with IgAN and 
proteinuria.19 Previous studies have shown that ACEIs alone 
or with angiotensin receptor–blocker therapy prevent progres-
sion of renal disease in patients with IgAN.20,21
All patients in the present study were treated with fish 
oil after diagnosis. Twenty-nine of 39 patients (74.4%) were 
treated with ACEIs, and ten (25.6%) with corticosteroids. 
Three (7.7%) patients had corticosteroid plus cytotoxic 
agents including cyclosporine-A, cyclophosphamide, and   
azathiopurine. Four patients with nephrotic syndrome, 
three patients with nephritic syndrome, two patients with 
  hematuria ± proteinuria and one patient with recurrent mac-
roscopic hematuria were given steroid therapy.
IgAN was initially thought to follow a benign course, 
but it is now recognized that slow progression to ESRD 
occurs in up to 50% of affected patients.16,22 The remain-
ing patients enter a sustained clinical remission or have 
persistent low-grade hematuria or proteinuria.22 However, 
the prognosis is quite variable and the outcome difficult to 
predict with accuracy in individual patients. In the European 
Renal Association chronic dialysis program for young adults, 
22% of patients were under 30 years of age.23 Short-term 
follow-up studies have shown a better prognosis for children, 
although long-term follow-up shows that IgAN in children 
is as progressive as in adults.4,24,25 Long-term studies have 
concluded that complete remission occurs in 5%–30% of 
patients.10 The majority of children with IgAN in this study 
admitted with macroscopic hematuria were found to have a 
good prognosis. In this study, 18 patients (46.1%) entered 
remission, which is a significantly higher proportion than in 
other studies reported to date.14,15
In 2004, the International IgA Nephropathy Network 
and the Renal Pathology Socienty established a working 
group to develop an international consensus on practical 
histopathological classification of IgAN.26,27 The Oxford clas-
sification is the largest-scale histopathological study of IgA 
nephropathy.26,27 This classification provides substantially 
stronger evidence for a histopathological grading system to 
predict renal prognosis of IgA nephropathy. Compared with 
the previous classifications, in the present study the Oxford 
classification was found to be practical and useful.
In children with progressive IgAN, the clinical course is 
often slow.16 Among the factors that determine   progression over 
the years are reduced renal function, persistent   hypertension, 
and proteinuria at onset.28–30 Four patients had hypertension at 
onset. One of these achieved remission, one had minor urinary 
abnormalities, and one had active renal disease while one 
developed renal failure. Twenty patients had proteinuria (.1 g/
day) at onset. Two of these had active renal disease while two 
developed renal failure. Patients initially presenting with high 
serum creatinine levels, excepting those who had nephritic pre-
sentations, did not show poor prognosis, as the creatinine levels 
of all these patients were regressed to normal ranges shortly 
after disease onset. None had active renal disease, or developed 
renal failure at last follow-up. However, the authors believe that 
careful monitoring of these patients should continue.
Conclusion
The outcome results of the patients in this study are better 
than those reported in most other studies. Early diagnosis and 
treatment of IgAN in childhood may bring important benefits 
and a favorable prognosis. The majority of children with 
IgAN in this study were admitted with recurrent macroscopic 
hematuria, which was found to have a good prognosis. In 
addition, this study has shown that histopathological findings 
do not correlate with the course of the disease and progress of 
chronic renal failure. Steroids are still important agents in the 
treatment of IgA nephropathy. If patients with hypertension, 
elevated creatinine levels, or proteinuria are identified and 
receive early treatment, the course of disease can be modified 
and most patients will have a favorable prognosis.
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